From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis.
Willeke M C van Roon-MomChantal FergusonAnnemieke M Aartsma-RusPublished in: Nucleic acid therapeutics (2023)